TrialJapanese journal of clinical oncology2022

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.

Kazuhito Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.